IDT ripples the science world with promising Ran protein discovery
The annual incidence of breast cancer (BC) in the UK is 50,000 and around 1,000 die from BC every month. 5/100 BC patients have metastasis when first diagnosed, and a further 35/100 will develop metastasis within 10 years, representing considerable disease burden. The challenge is predicting metastatic disease early enough to improve patient outcomes. Current research led by IDT has indicated that Ran-GTP and its link to c-MET could be used to predict prognosis in breast cancer patients early and effectively.
c-Met and its influence on cancer is well-studied, c- Met is a known resistance to chemotherapy and even recently has certain inhibitor drugs undergoing clinical trials for lung cancer treatment. However, present-day research carried out by IDT has shown that targeting Ran-GTP may be a more effective approach.
Additionally, it has been found that c-Met requires Ran-GTP to function, and so buy blocking Ran-GTP c-Met resistance to chemotherapy had been wiped. This promising revelation has given Ran-GTP as a high potential therapeutic target for breast cancer treatment.
Having published several papers on the topic in some of the most prestigious journals internationally. Global medical news services: Eurekalert, Medical News Today, MedicalXpress and Bradford newspaper The Telegraph and Argus interviewed our very own President and head of Research and Development Professor Mohamed El-Tanani about the exciting new work being carried out here at IDT. For more information and to view the full published articles please click the links below.